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NC-ND license (http://creativecommoBackground: Acute fulminant myocarditis (AFM) commonly presents as abrupt cardiogenic
shock with or without dysrhythmia. This study evaluated the impact of extracorporeal mem-
brane oxygenation (ECMO) on AFM-related hemodynamic compromise dysrhythmias. We also
reported the clinical experience of AFM at our hospital.
Methods: Eighteen children diagnosed with AFM were enrolled. Demographic variables, labo-
ratory data, and clinical courses were reviewed. Thirteen surviving patients with hemodynamic
compromise arrhythmia [complete atrioventricular block (CAVB) or ventricular tachycardia
(VT)] during hospitalization were divided into Group A (ECMO group; n Z 7) and Group B
(non-ECMO group; n Z 6).
Results: The overall survival rate was 78% (14/18). There were no cases of mortality after
ECMO was introduced at our hospital. Common symptoms at diagnosis included general malaise
(94%), gastrointestinal symptoms (89%), chest pain (56%), shortness of breath (56%), and
seizure/syncope (56%). In addition to abnormal cardiac enzyme levels, all patients displayed
elevated alanine aminotransferase levels during early disease stages. Electrocardiography at
diagnosis revealed dysrhythmia in 15 patients, namely, CAVB in 11 patients (61%) and VT in fourCardiology, Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung
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AFM-related hemodynamic compromise dysrhythmias 481patients (22%). During hospitalization, the dysrhythmia shifted from CAVB to VT in 10 patients
and from sinus tachycardia to VT in one patient. New episodes of VT were common (overall
occurrence rate, 83%). Although myocardial damage and dysfunction were more severe in
Group A, the time to rhythm recovery in this group was shorter than that in Group B (median
time, 1.7 days vs. 7.35 days, pZ 0.045). All surviving patients had normal ventricular function
at 6-month follow-up.
Conclusion: Hemodynamic compromise arrhythmia is common in AFM patients and may cause
rapid deterioration. Simply correcting sinus rhythm is not always sufficient because of myocar-
dium instability. Timely use of ECMO can improve the survival rate and shorten the time to
recapture sinus rhythm in AFM patients with CAVB or VT.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Acute fulminant myocarditis (AFM) is an inflammatory dis-
ease of the myocardium that presents with nonspecific
symptoms such as initial flu-like symptoms with an onset of
<14 days.1,2 AFM is rare but life threatening in children
because of its rapid and aggressive progression to conges-
tive heart failure or cardiogenic shock.1,3e7 Intensive car-
diovascular support including the administration of
inotropic agents, pacing devices, mechanical ventilation, or
mechanical circulatory support can be lifesaving. AFM is
commonly associated with hemodynamic compromise dys-
rhythmias such as complete atrioventricular block (CAVB)
or ventricular tachycardia (VT), which present with severe
symptoms. Such dysrhythmias can arise at the first visit or
following inotropic or antiarrhythmic agent administration.
In some cases, pacemaker implantation or cardioversion is
not effective in correcting cardiogenic shock, and emer-
gency extracorporeal membrane oxygenation (ECMO) may
be required. The prognosis and survival rate of pediatric
patients with AFM have improved with recent advances in
mechanical circulatory support and teamwork in pediatric
units.1,8e12 The goal of this study was to retrospectively
review the impact of ECMO on AFM-related hemodynamic
compromise dysrhythmias. The clinical presentations, car-
diac rhythm, criteria of diagnosis, treatment, and outcome
of pediatric patients with AFM were also reviewed.
2. Materials and methods
2.1. Study population
From July 1998 to October 2012, 18 children (younger than
18 years) with a diagnosis of AFM were enrolled in this
study. The study was retrospective, and data collection was
approved by the Institutional Review Board of Chang Gung
Memorial Hospital.
The diagnostic criteria for AFM were as follows: (1) acute
heart failure (left ventricular dysfunction or arrhythmia
with hemodynamic compromise) and rapid deterioration;
(2) history of flu-like illness within the preceding 2 weeks;
(3) no history of cardiomyopathy or heart disease; and (4)
elevation of cardiac enzyme levels [troponin I (TnI) orcreatine kinase (CK)-MB].1,2,11,13 Children with acute car-
diopulmonary failure with fulminant enterovirus 71 infec-
tion were excluded because their heart failure may not
have been caused by myocarditis, but may have possibly
been associated with neurogenic cardiac damage.14 One
patient with a drug reaction exhibiting eosinophilia and
systemic syndrome-related fulminant myocarditis, who was
treated successfully with ECMO, was excluded because of
the distinct pathologic etiology of the disease.15
2.2. Data collection
The collected data included demographic data, clinical
history, initial presentation on admission, and the results of
a series of laboratory tests. The record of clinical presen-
tation included fever, general malaise, fatigue, dizziness,
chest pain, shortness of breath, gastrointestinal (GI) tract
symptoms (nausea, vomiting, or abdominal pain), and
neurologic signs (seizure or syncope). Hypotension was
identified as systolic blood pressure 70 mmHg þ (age  2)
in children more than 1 year old.
Laboratory investigations for complete white blood cell
counts and the levels of C-reactive protein, glucose,
aspartate aminotransferase (AST), alanine aminotrans-
ferase, blood urea nitrogen, creatinine, CK, CK-MB, and TnI
were performed at diagnosis and during hospitalization.
Electrocardiography (ECG) and transthoracic echocardi-
ography were performed to evaluate rhythm and ventricu-
lar function, respectively, at diagnosis, during
hospitalization, and before discharge. Owing to their crit-
ical conditions, cardiac catheterization and endomyo-
cardial biopsy were not performed in any patients.
The indication for implantation of a temporary pace-
maker was CAVB with hypotension or low cardiac output.
The indications for ECMO included (1) ventricular
arrhythmia refractory to antiarrhythmic agents or defibril-
lation, (2) ventricular dysfunction with persistent hypo-
tension that could not be restored by conventional therapy
and maximal dosages of inotropic agents, and (3) CAVB
status post-pacemaker implantation with unstable
hemodynamics.
Hemodynamic compromise arrhythmia was identified as
CAVB, VT, or ventricular fibrillation with signs of low car-
diac output. Of the 14 surviving patients, 13 experienced
482 K.-M. Lin et alhemodynamic compromise arrhythmia during hospitaliza-
tion. These patients were divided into two groups: Group A
(ECMO group; nZ 7) and Group B (non-ECMO group; nZ 6).
Demographics, laboratory data, clinical course, treatment,
and prognosis were compared between the two groups to
assess differences between therapies and the advantages
of treatment options.
2.3. Statistical analysis
All statistical analyses were performed using Statistical
Package for Social Sciences version 19 (SPSS, Chicago, IL,
USA). Nonparametric data were expressed as the
mean  standard error or median (range). Demographic
details, laboratory data at admission, variables of clinical
courses, and treatment were analyzed. Clinical parameters
were compared as categorical variables between the two
groups using the Chi-square test or Fisher’s exact test, as
appropriate. Quantitative variables as comparisons of serial
differences were performed using the ManneWhitney U
test. A p value of <0.05 was considered significant.
3. Results
3.1. Clinical manifestation at diagnosis
The median age of the 18 children (9 boys and 9 girls) was
11.0 years (range, 4.0e15.3 years). Their median body
weight was 34.0 kg (range, 16.5e92.0 kg).
The clinical symptoms and physical findings identified in
the initial medical evaluation included general malaise or
dizziness (94%); GI symptoms such as poor appetite,
nausea, vomiting, and abdominal pain (89%); fever in theTable 1 Demographics and laboratory findings of patients with
Patient
no.
Onset
y
Sex Age
(y)
BW
(kg)
WBC count
(1000/mL)
CRP
(mg/L)
BUN/Cr
(mg/dL
1 1998 F 10.9 30 21.4 27.9 95/5
2 1998 M 7.8 30 6.0 3.4 9/ND
3 1999 M 5.9 21 10.1 26.6 20/ND
4 2000 M 8.6 26 9.3 3.4 16/0.9
5 2001 F 6.8 28 12.4 9.6 23/ND
6 2002 M 10.1 35 11.4 3.4 11/1.2
7 2003 M 11.7 34 9.1 30.6 15/0.6
8 2003 M 14 92 12.8 90.9 8/0.9
9 2004 F 13.4 42 5.1 11.4 16/0.8
10 2005 F 7.9 25 13.8 10.4 16/1
11 2005 F 10.2 40 13.8 2.2 21/0.8
12 2006 F 12.2 60 8.0 11.9 12/1.3
13 2010 F 15 43 8.2 75.7 18/0.76
14 2011 F 11.3 27 11.6 5.8 16/0.48
15 2011 F 11 45 6.7 6.4 16/0.79
16 2011 M 12.3 50 6.5 6.1 16/1.05
17 2011 M 15.3 57 9.7 72 20/1.87
18 2012 M 4 16.5 7.9 8.4 33/0.88
ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;
kinase; CK-MB Z creatine kinase MB isoenzyme; Cr Z creatine; CRP
mined; TnI Z troponin I; WBC Z white blood cell.previous 2 weeks (78%); chest pain/palpitation (56%);
shortness of breath (56%); and neurologic signs such as
syncope and seizure (56%).
Laboratory data at diagnosis are presented in Table 1.
Leukocytosis (white blood cell count exceeding 11,000/
mm3) was detected in seven patients (39%). Fourteen pa-
tients (78%) had mild C-reactive protein elevation (5 mg/
dL), but only three patients had C-reactive protein levels
>50 mg/dL. Hyperglycemia with a random serum glucose
level exceeding 140 mg/dL was detected in 11 patients
(61%). Hypoperfusion of end organs was evaluated by liver
enzyme, blood urea nitrogen, and creatinine levels. All 18
patients had abnormal AST levels at diagnosis (median,
173 U/L; range, 59e12,624 U/L), and 13 patients (72%) had
levels of three times the upper limit of the normal range,
with six patients (33%) transiently exhibiting AST levels of
10 times the upper limit of the normal range during hospi-
talization. Of the 14 surviving patients, eight had an
abnormal alanine aminotransferase level at diagnosis, and
only one (7%) had a level of three times the upper limit of
the normal range. Six patients (33%) had impaired renal
function at diagnosis. One patient (Case No. 15) received
continuous venovenous hemodialysis during ECMO support
on the 4th day of admission to treat rapidly deteriorating
renal function. The patient’s renal function had recovered
at discharge. Elevation of at least one cardiac enzyme
including TnI and/or CK-MB/CK was identified at diagnosis.
Of the 18 patients, 12 had an elevation in absolute TnI
levels (range, 13.59e104.56 ng/mL). Absolute CK-MB levels
were elevated in all patients (range, 17.0e273.3 ng/mL),
nine (50%) of whom also had abnormal CK-MB/CK ratios
(5%). Cardiac enzyme levels, liver function, and renal
function returned to normal in all surviving patients before
discharge.acute fulminant myocarditis at diagnosis.
)
AST/ALT
(U/L)
Sugar
(mg/dL)
TnI
(ng/mL)
CK-MB/CK
(U/L)
CK-MB/CK
(%)
12,624/ND 203 ND 47.1/3384 1.4
91/ND 254 ND 47.9/1020 4.7
75/ND 122 ND 17/417 2.4
173/30 101 ND 219/1751 12.5
145/ND 140 ND 40.3/737 5.5
155/43 164 >50 44.0/957 4.6
298/ND ND ND 122.4/4491 2.7
59/27 ND >50 43.7/849 5.1
171/51 127 >50 45.7/1121 4.1
518/178 252 >50 273.3/15,961 1.7
105/24 126 21.96 32/764 4.2
239/55 286 >22.78 45.6/2093 2.2
381/66 181 104.56 229.2/3140 7.3
85/18 107 13.59 72.8/480 15.2
217/98 149 58.51 187.7/ND
189/77 260 34.37 86.8/1024 8.5
189/116 282 25.3 76.2/606 12.6
149/28 214 30.75 95.2/1421 6.7
BUN Z blood urea nitrogen; BW Z body weight; CK Z creatine
Z C-reactive protein; F Z female; M Z male; ND Z not deter-
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dimensional echocardiography at diagnosis and
during hospitalization
ECG at diagnosis revealed that 11 patients (61.1%) had
CAVB. Specifically, four patients (22.2%) had VT, and three
patients (16.7%) had sinus tachycardia with ST segment
change and T-wave inversion. Cardiac rhythm shifts to new
episodes of VT commonly followed pacemaker implanta-
tion, pacing, or inotropic agent infusion. VT during hospi-
talization occurred in 15 patients (83.3%). Overall, 10 of 11
patients with initial CAVB and one of three patients with
sinus tachycardia at diagnosis later developed transient VT.
The overall incidence of hemodynamic compromise
arrhythmia was 88.9% (Figure 1).
Standard transthoracic two-dimensional echocardiogra-
phy was performed in 16 patients because of hemodynamic
instability at diagnosis. The median left ventricular ejec-
tion fraction in these patients was 28.4% (range,
12.3e69.6%). The median fractional shortening was 13.4%
(range, 5.8e38.9%). The left ventricular diastolic dimen-
sion, as measured by M-mode echocardiography in the
parasternal long axis view and corrected using body surface
area, did not exceed the upper limit, as a median of
40.3 mm (range, 35.2e59.0 mm) was recorded. The quali-
tative degree of mitral regurgitation (MR) was assessed in
16 patients, with moderate MR being noted in one patient
and trivial to mild MR in 14 patients. The remaining patient
had no MR at diagnosis.Figure 1 Electrocardiographic presentation at diagnosis and
during hospitalization. CAVB Z complete atrioventricular
block; VT Z ventricular tachycardia.3.3. Clinical course and treatment during
hospitalization
All patients required a high dosage of inotropic agents
(dopamine, dobutamine, milrinone, epinephrine, isopro-
terenol, or atropine) to maintain blood pressure and cardiac
function at admission. Cardioversion and antiarrhythmic
agents such as amiodarone or lidocaine were used to treat
VT. Of the 18 patients, eight (44%) received immune modu-
lation therapy, four received intravenous immunoglobulin at
a dose of 1 g/kg, which was repeated on the following day,
and four received steroid therapy (methylprednisolone:
30 mg/kg/dose, maximum 1 g/dose) for three consecutive
days. Cardiopulmonary resuscitation was performed for
eight patients (44%) (Table 2).
Four patients with VT at admission received cardiover-
sion and antiarrhythmic agents. Of these patients, two
(Case Nos. 5 and 10) died of refractory VT without the
timely use of ECMO, whereas the other two (Case Nos. 12
and 18) received ECMO support and survived with recovered
heart function.
Of the 18 patients, 11 had CAVB at admission, 10 of
whom developed VT later. VT was recorded in seven pa-
tients after temporary pacemaker implantation. Of these
patients, four (Case Nos. 1, 6, 9, and 11) were stabilized
with antiarrhythmic agents, two (Case Nos. 14 and 16)
required ECMO support because of refractory VT, and one
(Case No. 4) died without ECMO support. Dysrhythmias
shifted from CAVB to VT in three patients under treatment
with inotropic agents before pacemaker implantation. Of
these, two patients (Case Nos. 15 and 17) received ECMO
support, and the remaining patient (Case No. 3) recovered
soon after the administration of antiarrhythmic agents. ECG
in the latter patient (Case No. 3) revealed occasional VT
and second-degree atrioventricular block alternatively
after lidocaine injection. The time to recapture sinus
rhythm was also relatively short (0.8 days). The patient did
not undergo pacemaker implantation because of the rela-
tively stable condition following treatment with conven-
tional therapies and the short duration of dysrhythmia.
Three patients had sinus tachycardia at admission. The
condition shifted to VT in one of these patients (Case No.
13) after the infusion of inotropic agents, and this patient
received ECMO support. Meanwhile, the condition of one
patient (Case No. 8) stabilized under inotropic therapy, and
the remaining patient died despite therapy to control re-
fractory heart failure within 12 hours.
Seven patients received ECMO support. The median time
from admission to ECMO cannulation was 4 hours (range,
1e21 hours). The cannulation sites for ECMO were the
femoral artery and vein in five patients and the right ca-
rotid artery and internal jugular vein in two patients. The
indication of weaning off ECMO was evaluated in all pa-
tients after recapturing the sinus rhythm with evidence of
improvement in left ventricular contractility. All patients
were successfully weaned off ECMO with a median time of
98 hours (range, 70e141 hours). Complications of ECMO
included pseudoaneurysm at the cannulated site in one
patient and minor neurologic injury caused by peripheral
neuropathy in two patients.
Table 2 Clinical treatment and outcome of patients with acute fulminant myocarditis.
Patient no. Rhythm at diagnosis LVEF(%) at
diagnosis
Pacemaker VT after pacing
or inotropes
CPR IVIG Steroid
therapy
ECMO (h) Recapture of
sinus rhythm (d)
Outcome EKG at
discharge
LVEF at
discharge (%)
LVEF at
6 mo (%)
1 CAVB 17.8 + +    d 7.3 Survived NSR 84.2 59.7
2 CAVB 54 +     d 11.8 Survived NSR d 73.5
3 CAVB 65  + +   d 0.8 Survived NSR 68.6 58.7
4 CAVB 58 + + + +  d d Died d d d
5 VT ND  + +   d d Died d d d
6 CAVB 24.4 + +  +  d 8.6 Survived RBBB 59.7 69.6
7 Sinus tachycardia,
ST-T depression
37.3   +   d d Died d d d
8 ST-T change in I, II,
AVF, AVL, V3-V6
30.6      d d Survived NSR 53.6 66.0
9 CAVB 69.6 + +    d 5.0 Survived RBBB 72.1 66.0
10 VT ND  + +   d d Died d d d
11 CAVB 52.8 + +    d 7.4 Survived RBBB 78.1 64.8
12 VT 17.1  +  +  70 1.5 Survived NSR 65.0 61.1
13 Sinus tachycardia,
ST elevation in V123,
inverted T in II, III AVF
16.3  +   + 141 2 Survived NSR 55.3 66.1
14 CAVB 25.7 + + + +  132 4.3 Survived NSR 47.2 60.0
15 CAVB 26.1  +   + 98 3.2 Survived RBBB 77.8 64.1
16 CAVB 46.3 + + +  + 92 1.5 Survived NSR 70.3 66.1
17 CAVB 12.3  + +  + 97 1.2 Survived NSR 49.8 68.0
18 VT 15.9  +    107 1.7 Survived NSR 46.5 59.8
CAVB Z complete atrioventricular block; CPR Z cardiopulmonary resuscitation; ECMO Z extracorporeal membrane oxygenation; EKG Z electrocardiogram; IVIG Z intravenous
immunoglobulin; LVEFZ left ventricular ejection fraction; NSRZ normal sinus rhythm; RBBBZ right bundle branch block; ST-TZ EKG ST segment and T wave change; VTZ ventricular
tachycardia.
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AFM-related hemodynamic compromise dysrhythmias 485Regarding the laboratory data in the groups, the CK-MB
level at diagnosis was significantly higher in Group A than in
Group B (median: 86.8 U/L vs. 44.9 U/L, p Z 0.01). Left
ventricular function, as evaluated by left ventricular
ejection fraction, was weaker in Group A than in Group B at
diagnosis (median: 17.1% vs. 53.4%, p Z 0.032). However,
the time to recapture sinus rhythm was shorter in Group A
than in Group B (median time: 1.7 days vs. 7.35 days,
p Z 0.045) (Table 3). Thus, although myocardial damage
and dysfunction were more severe in Group A, the time to
rhythm recovery was shorter in Group A than in Group B.
Meanwhile, 78% of patients survived to hospital
discharge. All seven patients who were supported with
ECMO survived. Of the four nonsurviving patients, three
died due to VT. ECG performed before discharge in surviv-
ing patients revealed a normal sinus rhythm in 10 patients
and right bundle branch block in four patients. There were
no statistically significant differences between the groups
regarding left ventricular contractility before and 6 months
after discharge. All surviving patients exhibited recovery of
normal ventricular function at the 6-month follow-up visit.
No patients received long-term oral medication to control
heart failure or required heart transplantation.4. Discussion
Based on the published literature, myocarditis is difficult to
categorize into acute nonfulminant and acute fulminant
types, and endomyocardial biopsy is required for pathologic
classification and predictions of prognosis.1e3 Endomyo-
cardial biopsy is not routinely performed in patients sus-
pected to have AFM because of the risks of the procedure in
patients in critical condition.16 In this study, AFM was
diagnosed on the basis of patient history, characteristics of
acute heart failure or arrhythmia with hemodynamicTable 3 Admission laboratory values and clinical course of su
according to the receipt of ECMO.
Group A:
ECMO (n Z 7
Age (y) 12.2 (4.0e
BW (kg) 45.0 (16.5e
WBC (k/mL) 8.5 (6.5e
CRP (mg/dL) 8.4 (5.8e
AST (U/L) 189 (85e3
Cr (mg/dL) 0.80 (0.48e
CK-MB (U/L) 86.8 (45.6e
CK (U/L) 1222.5 (480.0
LVEF at diagnosis (%) 17.1 (12.3e
VT episodes 7 (100%
CPR episodes 3 (43%)
Pacemaker implantation 2 (29%)
Duration of returning to sinus rhythm (d) 1.7 (1.2e
LVEF before discharge (%) 55.3 (46.5e
LVEF after 6 mo (%) 64.1 (59.8e
Continuous variables are expressed as the median (interquartile rang
AST Z aspartate aminotransferase; BW Z body weight; CK Z creatin
resuscitation; Cr Z creatine; CRP Z C-reactive protein; ECMO Z
ejection fraction; VT Z ventricular tachycardia; WBC Z white bloodcompromise and rapid deterioration, and a recent (within
2 weeks) history of flu-like illness. The differential diag-
nosis of AFM, cardiomyopathy, or other heart diseases can
be evaluated by echocardiography. Left ventricular cavity
size (left ventricular diastolic dimension) can be used to
evaluate left ventricular dimensions, and the dimensions of
this area are relatively normal in patients with suspected
fulminant myocarditis.17,18 In addition, brain natriuretic
peptide and cardiac enzyme (TnI or CK-MB) levels during
the acute stage can help differentiate between acute
nonfulminant myocarditis, AFM, and cardiomyopathy.
In addition to a rapid and aggressive course, AFM can
initially present with nonspecific symptoms and signs that
pose diagnostic challenges for physicians. Chien et al19
described hypotension and StokeseAdam seizures as more
specific manifestations of acute myocarditis with CAVB.
Hsiao et al5 also mentioned GI symptoms as common initial
presentations and predictors of poor prognosis. Among
studied laboratory tests, Freedman et al20 reported that
AST testing might be a useful adjunctive analysis for pa-
tients with early-stage AFM. In our study, early GI symptoms
and neurologic signs were important clues of end-organ
hypoperfusion. In some cases, these chief complaints
were more specific and they appeared earlier than chest
pain, palpitation, or dyspnea when patients visited the
emergency department. Our laboratory findings illustrated
that AST measurement was the most sensitive and
nonspecific test excluding cardiac enzyme analyses, with
all patients displaying abnormal findings at the initial
diagnosis. In such cases, careful evaluation of heart rhythm
and other signs of heart failure are important before
obtaining data for specific cardiac enzymes.
Dysrhythmias are common and severe in patients with
AFM. Abe et al21 described CAVB as the development of
conduction system injury via inflammation and reported
that 14 (58%) of 24 patients with acute myocarditis hadrviving patients with hemodynamic compromise arrhythmia
)
Group B:
Non-ECMO (n Z 6)
p
15.3) 10.2 (5.9e14.0) 0.116
60.0) 32.5 (21.0e42.0) 0.153
11.6) 10.8 (5.1e21.4) 0.475
75.7) 7.4 (2.2e27.9) 0.317
81) 130 (75e12,624) 0.252
1.87) 1.00 (0.80e5.00) 0.340
239.7) 44.9 (17.0e47.9) 0.010
e3140.0) 988.5 (417.0e3384.0) 0.631
46.3) 53.4 (17.8e69.6) 0.032
) 5 (83%) 0.462
1 (17%) 0.559
5 (83%) >0.99
4.3) 7.35 (0.8e11.8) 0.045
77.8) 72.1 (59.7e84.2) 0.062
68.0) 65.4 (58.7e73.5) 0.886
e).
e kinase; CK-MB Z creatine kinase-MB; CPR Z cardiopulmonary
extracorporeal membrane oxygenation; LVEF Z left ventricular
cell.
486 K.-M. Lin et aladvanced atrioventricular block, CAVB, or VT at the acute
stage. Teele et al1 also documented abnormal rhythm, as
shown by VT or CAVB in 11 (55%) of 20 patients with AFM on
admission, and 80% of patients developed additional he-
modynamic compromise arrhythmia during hospitalization.
In our study, the overall occurrence rate of hemodynamic
compromise arrhythmia admission was 88.9% in patients
with AFM, most of whom (83%) had VT.
The mechanism underlying VT resulting from AFM with
CAVB or sinus tachycardia remains unclear. Klein et al22
found that inflammatory processes in the myocardium can
directly lead to fluctuations in membrane potential.
Ectopic pacemakers, late potentials, and re-entry as a
result of inhomogeneous stimulus conduction can develop
because of fibrosis and scaring of myocardial tissue, and
secondary hypertrophy and atrophy of myocytes. Further-
more, left ventricular dysfunction may aggravate wall
tension, increase myocardial oxygen consumption, and
diminish coronary reserve, increasing the risk of arrhyth-
mias.23 The combination of myocardial instability and left
ventricular dysfunction may explain the common and sud-
den induction of VT after inotropic agent or isoproterenol
administration in our study.
In some cases, antiarrhythmic agents or cardioversion is
not effective in resolving VT and preserving heart function.
As reported in the previous literature, ECMO was instituted
emergently in our patients because of refractory cardio-
genic shock and end-organ dysfunction.6,8e11,13,24e26 ECMO
facilitates ventricular recovery by reducing myocardial wall
tension, increasing coronary perfusion pressure, and
providing adequate systemic perfusion. During ECMO sup-
port, the dose of inotropes can be decreased to prevent
overload on the myocardium in the acute stage. Better
cardiac support may promote the recovery of cardiac con-
duction. This may explain the shorter duration of dys-
rhythmias in the ECMO group than in the non-ECMO group in
our study.
Despite having a more aggressive disease course and a
higher risk of life-threatening disease, patients with AFM
had better outcomes in terms of recovery of ventricular
function and atrioventricular conduction than those with
the nonfulminant type. Among the surviving patients in this
study, all cases of arrhythmias resolved within 2 weeks,
with no patients requiring a permanent pacemaker or heart
transplantation. Meanwhile, three of the four nonsurviving
patients, who died of VT and heart failure refractory to
medical treatment, were treated prior to the introduction
of ECMO support. Owing to advances in critical care and the
introduction of ECMO in the clinic, the survival and long-
term prognosis of patients with AFM have increased.27 In
our study, there were no cases of mortality among patients
with AFM at our hospital after ECMO was introduced if
support was provided in a timely manner.
This study has several limitations. First, the data and
clinical findings were collected retrospectively via chart
reviews. In addition, we enrolled patients with AFM strictly
to distinguish them from patients with the nonfulminant
type. This may have led to a small sample size, which limits
complex statistical analysis.
In conclusion, hemodynamic compromise arrhythmia is
common in patients with AFM, and it can cause rapid
deterioration during hospitalization. Simply correctingrhythm is not always sufficient because of myocardium
instability. Timely use of ECMO can improve survival rates
and shorten the time to recapture sinus rhythm in AFM
patients with CAVB or VT. Among our surviving patients, all
arrhythmias resolved, and no patient required a permanent
pacemaker or heart transplantation.Conflicts of interest
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